Arvinas logo
Close this search box.

Propelling the Future

With Targeted Protein Degradation


April 11, 2024

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

Our Mission
is to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC® protein degradation platform.

Smiling male Arvinas staffer conducting experiment

We are Arvinas, a clinical-stage biotechnology company leading the way in the development of targeted protein degradation therapeutics.

We are singularly focused on developing an entirely new class of medicines that aims to be transformative for patients and their health care providers, turning targeted protein degradation into one of the promising areas of medical research and challenging the perceived limits of drug discovery.

Smiling Arvinas scientific staff member talking with colleague
Arvinas scientific staff

If you’re inspired, please take a look at the current list of opportunities to join our team.

Our Hope is to Revolutionize Drug Discovery

Our team is driving some of the significant breakthroughs in the industry and enabling an expansive pipeline of targets in oncology and neuroscience.

Together, we are bringing novel investigational research to patients who need it most. With multiple products in development, we are exploring how PROTAC® protein degraders bridge our preclinical platform into the clinic.

Learn more about our therapeutic programs.


Leading the Way with Innovation

Every day at Arvinas, we work to advance pioneering science to develop new, transformative treatments for patients with limited treatment options, or for whom existing treatments have not been effective.
Arvinas scientific staff preparing materials for testing
Arvinas scientific staff conducting tests through glass partition

This year marks a monumental milestone in Arvinas’ history as we celebrate our 10-year anniversary. Over the past decade, Arvinas has made incredible strides in pioneering targeted protein degradation research.

More →

We embrace the freedom to pursue innovation, think creatively and continually strive to create a diverse, equitable and inclusive colleague community—and we actively recruit talent who share these values. Explore our open positions to learn more.

More →

Arvinas is rooted in scientific innovation and is committed to bringing new options to patients living with life-threatening and life-altering diseases, especially cancer and neurologic disorders.

More →

We are unwavering in our mission to bring new treatments to patients through targeted protein degraders. We strive to be a trusted ally to the patient advocacy community and work to better understand the needs of patients, their families, and caregivers as we advance our drug development process.

More →

Our proprietary PROTAC® protein degrader technology was built upon groundbreaking research of our founder Dr. Craig Crews of Yale University, and we are especially proud of our New Haven roots. Beyond drug development, we are committed to our emerging biotechnology community in New Haven.

More →

We’re very social. Join the conversation with us on Twitter or LinkedIn!


More →


We partner with leading drug companies, academic experts, and innovative partners to further broaden and accelerate our clinical programs.

More →

Smiling Arvinas scientific staff member talking with colleague
Arvinas scientific staff preparing materials for testing
Smiling Arvinas scientific staff member talking with colleagues

We’re excited about the work we’re doing inside and outside of Arvinas, and think you will be, too.


You are now leaving Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

Skip to content